ClinConnect ClinConnect Logo
Search / Trial NCT02955316

Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China

Launched by ASTRAZENECA · Nov 2, 2016

Trial Information

Current as of April 24, 2025

Completed

Keywords

ClinConnect Summary

This is a multicentre, nationwide and cross-sectional study carried out in China, covering 30 sites and 3000 patients totally. As for the ratio of tertiary to secondary general hospitals is approximately 1:4 in China, 6 tertiary and 24 secondary hospitals will be randomly selected in this study.To adapt the representativeness of the data with the operational feasibility, 30 tertiary and 120 secondary hospitals will be randomly selected over the 6 geographic regions (north, northeast, east, south central, southwest and northwest). Among those, 1 tertiary and 4 secondary hospitals in each reg...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Provision of subject informed consent
  • 2. Consecutive female and/or male GI outpatients aged 18 years and over
  • Exclusion Criteria:
  • 1. Subject with a cognitive condition and unable to finish the questionnaire
  • 2. Subject has an acute or chronic non-GI condition; e.g., doesn't record a 'yes' response to the question, 'Do you have a gut problem?'

Trial Officials

Xiaohua Hou, PhD

Study Chair

Wuhan Union Hospital, China

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials